Targeted delivery of BDNF-loaded poly (lactide-co-glycolide) nanoparticle to the brain: penetration through blood brain barrier and neuroprotective effect in stroke / Siti Norsyafika Kamarudin by Kamarudin, Siti Norsyafika
 UNIVERSITI TEKNOLOGI MARA 
TARGETED DELIVERY OF  
BDNF-LOADED POLY  
(LACTIDE-CO-GLYCOLIDE) 
NANOPARTICLE TO THE BRAIN: 
PENETRATION THROUGH  
BLOOD BRAIN BARRIER AND 
NEUROPROTECTIVE  
EFFECT IN STROKE 
 
 
SITI NORSYAFIKA BINTI KAMARUDIN 
 
 
Thesis submitted in fulfillment  












Stroke remains a major public health burden in Malaysia due to high morbidity and 
mortality. Neuroprotection by Brain derived neurotrophic factor (BDNF) has the 
potential to minimise the ischemic damage and theoretically improve freedom from 
disability among stroke survivors. There is a need to develop nanoparticle (NP) drug 
delivery system to deliver BDNF following intravenous route after the ischemic insult 
due to poor penetration to the brain. In this study we proposed to design BDNF-loaded 
poly (lactide-co-glycolide) (PLGA) nanoparticles (BDNF-NPs) and to study 
neuroprotective effect of BDNF on permanent middle cerebral artery occlusion 
(pMCAO) model of ischemia in rats. BDNF containing PLGA nanoparticles were 
synthesized using water/oil/water (W/O/W) double emulsion solvent evaporation 
method. The nanoparticles were characterized for particle size (PS) and zeta potential 
(ZP) using a dynamic light scattering (DLS) technique. The percentage entrapment 
efficiency (%EE) was calculated. Penetration of blood brain barrier (BBB) was 
studied using an in vitro model employing human brain microvascular endothelial 
cells (HBMECs). The PS and ZP of NPs were found to be 186.6 nm and -18.6 mV 
respectively with 93% EE. Confocal laser scanning microscopy (CLSM) confirmed 
penetration and distribution of fluorescent NPs using Coumarin 6 as fluorescent probe 
into HBMECs and the number of NPs entering the cells was measured. 
Apolipoproteins (Apo) role in the NP uptake was investigated using ApoE, B100, A1 
or C2, incubated with HBMECs. Cell viability was determined using MTS-assay. 
BDNF release into cells was quantified using ELISA method. No cytotoxicity of Apo-
coated/non-coated PLGA NPs was observed. The fluorescent intensity was found to 
be significantly higher for ApoE-coated NPs compared to ApoA1-coated NPs (1.31 
folds, p<0.001) and control, not coated NPs (4.06 folds, p<0.001). The fluorescent 
intensity of ApoB100-coated NPs was significantly higher compared to control group 
by 3.88 folds (p<0.001). Significantly higher concentration of BDNF was found in 
HBMECs after treatment with Apo E- and Apo B100-coated NPs compared to control 
group by 69.31 (p<0.001) and 57.46 folds (p<0.001) respectively. The final step was 
to test neuroprotective effect of BDNF-NPs on pMCAO model of ischemia in rats. 
Sprague-Dawley rats were divided into 4 groups of 7 rats each. Group 1 was subjected 
to sham operation, group 2, 3 and 4 were subjected to pMCAO. Four hours after 
pMCAO, group 3 and 4 were intravenously treated with BDNF and BDNF-NPs 
respectively. Functional outcome was assessed at 2 h and 24 hours after pMCAO 
using modified Neurologic Severity Score (mNSS), rotarod and grid walking. Rats 
were sacrificed by terminal cardiac puncture, blood was taken for assessment of 
neurobiomarkers (NSE and S100β) level and brain was subjected for infarct area 
assessment and volume measurement. BDNF-NPs treated group showed significant 
improvement in mNSS when compared with pMCAO and BDNF treated groups 
demonstrating decreased mNSS score by 2.0 and 2.0 times. BDNF-NPs treated group 
showed improved rotarod performance by increasing latency time on rotarod by 2.44 
(p<0.001) and 2.76 folds (p<0.001) when compared with pMCAO and BDNF treated 
groups. The infarct volume in rats treated with BDNF-NPs was significantly smaller 
by 1.91 and 1.95 folds (p<0.001) when compared with pMCAO and BDNF treated 
groups. The results were further corroborated by the estimation of neurobiomarkers 
(NSE and S100β) level. Overall, BDNF loaded PLGA nanoparticle is a promising 
drug formulation that act as neuroprotective agent in ischemic stroke model. 
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 Stroke is a major public health burden as it is the second leading cause of 
death and a major cause of physical disability worldwide (Katan & Luft, 2018). 
Current statistics from the Global Burden of Disease, Injuries, and Risk Factors Study 
(GBD 2015) revealed a further shift from communicable diseases, maternal, and 
nutritional causes towards noncommunicable diseases like stroke. This occurance is 
likely due to an increment in aging of the world's population as well as a decrease in 
death rates globally in recent decades (Wang et al., 2016). The most prominent causes 
of death are vascular in nature, and stroke is currently the second leading cause of 
death worldwide (Feigin et al., 2017). Ischaemic heart disease and stroke together 
accounted for 15.2 million deaths (15–15.6 million) in 2015 (Feigin et al., 2017). 
While ischaemic strokes comprise the highest number of strokes, much of the global 
burden of stroke measured in proportion to mortality and disability-adjusted life-years 
(DALYs) are allocated to haemorrhagic stroke (Feigin, Norrving & Mensah, 2017).  
A year 2008 study found that stroke consumed about 2-4% of total health care 
costs worldwide and accounted for more than 4% of direct health care costs in 
industrialized countries (Donnan, Fisher, Macleod & Davis, 2008).  
In developed countries, the incidence and prevalence of stroke are decreasing 
whereas in the Asia Pacific the number of patients diagnosed with acute ischaemic 
stroke is on the rise (Aziz et al., 2015). Department of Statistics Malaysia revealed a 
report in 2017, stated that, in Malaysia, stroke is the number three cause of death after 
ischaemic heart disease and pneumonia.  
Clinically, stroke can be defined as an umbrella of conditions caused by the 
occlusion or haemorrhage of cerebral blood vessels supplying the brain (Lo, Dalkara 
& Moskowitz, 2003). In all instances, it will involve death or the dysfunction of 
neuronal cells and neurological deficits that reflect the location and size of the 
compromised brain area (Lo, Dalkara & Moskowitz, 2003). Ultimately, it is a leading 
cause of death and long-lasting physical disability, requiring fast and definite 
treatment (Keyser, Sulter & Luiten, 1999).  
